|
gptkbp:instanceOf
|
antifungal medication
triazole antifungal
|
|
gptkbp:approvalYear
|
1990
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J02AC01
|
|
gptkbp:availableOn
|
gptkb:tablet
intravenous solution
oral suspension
|
|
gptkbp:brand
|
gptkb:Canesten_Oral
gptkb:Diflucan
gptkb:Trican
|
|
gptkbp:CASNumber
|
gptkb:86386-73-4
|
|
gptkbp:chemicalFormula
|
C13H12F2N6O
|
|
gptkbp:contraindication
|
hypersensitivity to fluconazole
concomitant use with certain drugs (e.g., terfenadine, cisapride)
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredIn
|
1982
|
|
gptkbp:eliminationHalfLife
|
20-50 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluconazole
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:phenytoin
gptkb:rifampin
gptkb:theophylline
gptkb:warfarin
statins
oral hypoglycemics
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
inhibits fungal cytochrome P450 enzyme 14α-demethylase
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
306.27 g/mol
|
|
gptkbp:pregnancyCategory
|
C (low dose, US)
D (high dose, US)
|
|
gptkbp:riskFactor
|
gptkb:Stevens-Johnson_syndrome
QT prolongation
hepatotoxicity
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
headache
rash
elevated liver enzymes
|
|
gptkbp:usedFor
|
prevention of fungal infections in immunocompromised patients
treatment of candidiasis
treatment of cryptococcal meningitis
treatment of fungal infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Candidiasis
gptkb:Cryptococcosis
gptkb:CYP2C9
gptkb:Candida
|
|
gptkbp:bfsLayer
|
5
|